Taken together, these findings strongly suggest that the downregulation of MAGI3 expression in ccRCC patients initiates MAS/ERK signaling activation, contributing to Sunitinib resistance. This evidence concerns the gene MAS1 and nonpapillary renal cell carcinoma.